Since its 2019 web launch, you have shown great interest in the OnTarget resource and we thank you!
In order to be able to continue to offer you quality information and to ensure the sustainability of the project, moving forward, a fee will be associated with the available continuing education activities. However, access to complete scientific content will remain free.
Stay tuned for the new continuing education offer that will be available in spring 2021!
OnTarget aims to help pharmacists and other health care professionals counsel patients receiving
targeted therapies for the treatment of cancer and manage the adverse events that may occur.
This program was made possible due to the support of the GEOQ and to unrestricted grants provided by the
following pharmaceutical companies: AbbVie Corporation, Amgen Canada Inc. Astra Zeneca Canada, Boehringer
Ingelheim Canada Ltd., Bristol-Myers Squibb Canada Co., Eisai Limited, Eli Lilly Canada Inc., Gilead
Sciences Canada Inc., GlaxoSmithKline, Hoffman-La Roche Ltd., Janssen Inc., Merck Canada Inc., Novartis Pharmaceuticals
Canada Inc., Paladin Lab inc., Pfizer Canada Inc., Sanofi Canada and Takeda Canada Inc.